Phathom Pharmaceuticals (PHAT) Other Non Operating Income (2019 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Other Non Operating Income of -$24000.0 for Q2 2026, up 84.52% year-over-year from -$13007.0 in Q2 2025, and up 97.11% quarter-over-quarter from -$831000.0 in Q1 2026.
Powered by 
Analysis
Phathom Pharmaceuticals (PHAT) Other Non Operating Income (2019 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Other Non Operating Income for 8 consecutive years, with -$24000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Non Operating Income rose 84.52% year-over-year to -$24000.0; the TTM figure through Jun 2026 stood at -$867000.0 (down 537.5% YoY), while the FY2025 annual figure was -$190000.0, down 2275.0% from the prior year.
- Other Non Operating Income climbed to -$24000.0 in Q2 2026 per PHAT's latest filing, from -$831000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $49000.0 in Q4 2024 and bottomed at -$831000.0 in Q1 2026.
- Historically, Other Non Operating Income has averaged -$75000.0 across 5 years, with a median of -$9500.0 in 2022.
- Annual changes were most pronounced in 2024 — Other Non Operating Income surged 450.0% — and 2026, when it plunged 3677.27%.
- Phathom Pharmaceuticals' Other Non Operating Income stood at -$90000.0 in 2022, then jumped by 84.44% to -$14000.0 in 2023, then soared by 450.0% to $49000.0 in 2024, then tumbled by 110.2% to -$5000.0 in 2025, then plunged by 380.0% to -$24000.0 in 2026.
- Business Quant data shows PHAT's Other Non Operating Income at -$24000.0 in Q2 2026, -$831000.0 in Q1 2026, and -$5000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Phathom Pharmaceuticals | 784.71 Mn | 599.37 Mn | 59.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -24,000.00 |
| Mar 31, 2026 | -831,000.00 |
| Dec 31, 2025 | -5,000.00 |
| Sep 30, 2025 | -7,000.00 |
| Jun 30, 2025 | -155,000.00 |
| Mar 31, 2025 | -22,000.00 |
| Dec 31, 2024 | 49,000.00 |
| Sep 30, 2024 | -8,000.00 |
| Jun 30, 2024 | -6,000.00 |
| Mar 31, 2024 | -43,000.00 |
| Dec 31, 2023 | -14,000.00 |
| Sep 30, 2023 | -197,000.00 |
| Jun 30, 2023 | 3,000.00 |
| Mar 31, 2023 | 20,000.00 |
| Dec 31, 2022 | -90,000.00 |
| Sep 30, 2022 | -11,000.00 |
| Jun 30, 2022 | -2,000.00 |
| Mar 31, 2022 | -7,000.00 |
| Dec 31, 2021 | -17,000.00 |
| Sep 30, 2021 | -2.05 Mn |